title: 2-Deoxy-d-Glucose (2-DG)-Induced Cardiac Toxicity in Rat: NT-proBNP and BNP as Potential Early Cardiac Safety Biomarkers.
abstract: 2-Deoxy-d-glucose (2-DG) is being developed as a potential anticonvulsant and disease-modifying agent for patients with epilepsy; however, during preclinical development, cardiac toxicity has been encountered in rats. This study was performed to determine whether cardiac troponin (cTnI and cTnT), atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), N-terminal pro-brain natriuretic peptide (NT-proBNP), and/or creatine kinase (CK) could be useful as indicators of 2-DG cardiac toxicity. In addition, this study also investigated the association of cardiac histopathological changes with these biomarkers. F344 rats (4/sex/group/sacrifice point) were gavaged with either vehicle or 2-DG (50, 125, or 375 mg/kg twice daily; total daily dose of 100, 250, or 750 mg/kg/d) for 7, 14, 21, or 45 days followed by a 15-day recovery. Dose-dependent increases in NT-proBNP and BNP plasma concentrations were observed. Following recovery period, the NT-proBNP and BNP concentrations returned to baseline levels. There were no remarkable increases in CK, ANP, cTnI, or cTnT concentrations. There were no gross cardiac lesions observed at the necropsy. Microscopic findings of vacuolar degeneration and hypertrophy of the endothelial cells of the endocardium were present in the heart at doses of 250 and 750 mg/kg/d. Microscopic findings, in general, were associated with increases in NT-proBNP levels. Cardiac toxicity appeared to be reversible. In conclusion, NT-proBNP and BNP are potential early biomarkers for 2-DG-induced cardiac toxicity that can be useful to monitor 2-DG therapy in clinical trials.
authors.affiliation: National Center for Advancing Translational Sciences, Bethesda, MD, USA tersep@mail.nih.gov.
authors.forename: P S
authors.initials: PS
authors.lastname: Terse
authors.affiliation: National Center for Advancing Translational Sciences, Bethesda, MD, USA.
authors.forename: P S
authors.initials: PS
authors.lastname: Joshi
authors.affiliation: Battelle Memorial Institute, Columbus, OH, USA Covance, Greenfield, IN, USA.
authors.forename: N R
authors.initials: NR
authors.lastname: Bordelon
authors.affiliation: Battelle Memorial Institute, Columbus, OH, USA.
authors.forename: A M
authors.initials: AM
authors.lastname: Brys
authors.affiliation: Battelle Memorial Institute, Columbus, OH, USA.
authors.forename: K M
authors.initials: KM
authors.lastname: Patton
authors.affiliation: Battelle Memorial Institute, Columbus, OH, USA Covance, Madison, WI, USA.
authors.forename: T P
authors.initials: TP
authors.lastname: Arndt
authors.affiliation: University of Wisconsin, Madison, WI, USA.
authors.forename: T P
authors.initials: TP
authors.lastname: Sutula
mesh_terms: D000818:Animals; D015415:Biomarkers / Q000097:blood; D006332:Cardiomegaly / Q000097:blood / Q000139:chemically induced* / Q000473:pathology; D003847:Deoxyglucose / Q000633:toxicity*; D005260:Female; D006321:Heart / Q000187:drug effects; D008297:Male; D009206:Myocardium / Q000473:pathology; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D010446:Peptide Fragments / Q000097:blood*; D051381:Rats; D011916:Rats, Inbred F344; D014617:Vacuoles / Q000187:drug effects / Q000473:pathology
chemical_list: D015415:Biomarkers; D010446:Peptide Fragments; C109794:pro-brain natriuretic peptide (1-76); D020097:Natriuretic Peptide, Brain; D003847:Deoxyglucose
keywords: 2-deoxy-d-glucose; BNP; NT-proBNP; vacuolar degeneration
references.citation: Lancet. 2003 Jul 26;362(9380):316-22
references.pmid: 12892964
references.citation: Nature. 2003 Jul 3;424(6944):35-41
references.pmid: 12840750
references.citation: J Neurochem. 1973 Sep;21(3):507-20
references.pmid: 4270246
references.citation: Pediatr Res. 1976 May;10(5):536-40
references.pmid: 934725
references.citation: Muscle Nerve. 1983 Feb;6(2):83-90
references.pmid: 6855802
references.citation: Circulation. 1996 Jun 1;93(11):1963-9
references.pmid: 8640969
references.citation: Mol Cell Biochem. 1999 Jan;190(1-2):9-32
references.pmid: 10098965
references.citation: Prog Neurobiol. 2005 Jan;75(1):1-28
references.pmid: 15713528
references.citation: Expert Opin Drug Saf. 2005 May;4(3):457-72
references.pmid: 15934853
references.citation: Cardiovasc Res. 2005 Oct 1;68(1):8-17
references.pmid: 15993390
references.citation: Heart. 2006 Jun;92(6):843-9
references.pmid: 16698841
references.citation: Biomed Environ Sci. 2006 Apr;19(2):96-103
references.pmid: 16827179
references.citation: Exp Oncol. 2007 Dec;29(4):309-13
references.pmid: 18199989
references.citation: J Am Coll Cardiol. 2007 Nov 27;50(22):2173-95
references.pmid: 18036459
references.citation: Nat Neurosci. 2006 Nov;9(11):1382-7
references.pmid: 17041593
references.citation: Exp Mol Pathol. 2008 Oct;85(2):90-5
references.pmid: 18721805
references.citation: Handb Exp Pharmacol. 2009;(191):341-66
references.pmid: 19089336
references.citation: Ann Neurol. 2009 Apr;65(4):435-47
references.pmid: 19399874
references.citation: Indian J Physiol Pharmacol. 2008 Jul-Sep;52(3):243-8
references.pmid: 19552054
references.citation: Toxicol Appl Pharmacol. 2010 Mar 15;243(3):332-9
references.pmid: 20026095
references.citation: Coron Artery Dis. 2010 Jun;21(4):244-56
references.pmid: 20351549
references.citation: Epilepsia. 2011 Sep;52(9):1609-16
references.pmid: 21762439
references.citation: Br J Cancer. 2011 Nov 22;105(11):1663-8
references.pmid: 22068815
references.citation: Int J Toxicol. 2013 Sep-Oct;32(5):351-7
references.pmid: 24055824
references.citation: Biochim Biophys Acta. 2013 Dec;1832(12):2442-50
references.pmid: 23313577